Inotropes do not increase mortality in advanced heart failure

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 237-251

  Guglin, Maya ^a   Kaufman, Marc ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Dobutamine; Heart failure; Inotropes; Milrinone

Indexed keywords

CARDIOVASCULAR AGENT; DOBUTAMINE; INOTROPE DERIVATIVE; MILRINONE; UNCLASSIFIED DRUG;

CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART PROTECTION; HEMODYNAMICS; HOME CARE; HOSPITAL MANAGEMENT; HUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 84901324542     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S62549     Document Type: Review

References (88)

1. Follath F, Yilmaz MB, Delgado JF, etal. Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF). Intensive Care Med. 2011;37:619-626.
2. Rose EA, Gelijns AC, Moskowitz AJ, etal. Long-term use of a left ventricular assist device for end-stage heart failure. New Engl J Med. 2001;345:1435-1443.
3. Yancy CW, Jessup M, Bozkurt B, etal; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College Of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239.
4. Lindenfeld J, Albert NM, Boehmer JP, etal. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-e194.
5. McMurray JJ, Adamopoulos S, Anker SD, etal. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis And Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
6. Jessup M, Banner N, Brozena S, etal. Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant. 2006;25:1003-1023.
7. Feldman D, Pamboukian SV, Teuteberg JJ, etal. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157-187.
8. Costanzo MR, Dipchand A, Starling R, etal. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914-956.
9. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: A new synthetic cardioactive sympathetic amine. New Engl J Med. 1979;300:17-22.
10. Baim DS, McDowell AV, Cherniles J, etal. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. New Engl J Med. 1983;309:748-756.
11. Vallet B, Dupuis B, Chopin C. [Dobutamine: mechanisms of action and use in acute cardiovascular pathology]. Ann Cardiol Angeiol (Paris). 1991;40:397-402. French.
12. Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci. 1987;294:244-248.
13. Colucci WS, Denniss AR, Leatherman GF, etal. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest. 1988;81:1103-1110.
14. Young RA, Ward A. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. 1988;36:158-192.
15. Pi Y, Zhang D, Kemnitz KR, Wang H, Walker JW. Protein kinase c and a sites on troponin i regulate myofilament ca2+ sensitivity and atpase activity in the mouse myocardium. J Physiol. 2003;552:845-857.
16. Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation. 1986;73:III175-III183.
17. Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol. 1996;28:1775-1780.
18. Pamboukian SV, Carere RG, Webb JG, etal. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant. 1999;18:367-371.
19. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and-5 inhibition. J Heart Lung Transplant. 2009;28:676-682.
20. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J. 1991;121:1956-1964.
21. Klocke RK, Mager G, Kux A, Hopp HW, Hilger HH. Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J. 1991;121:1965-1973.
22. Biddle TL, Benotti JR, Creager MA, etal. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987;59:1345-1350.
23. Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation. 1986;73:III168-III174.
24. Stevenson LW. Clinical use of inotropic therapy for heart failure: Looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation. 2003;108:367-372.
25. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001;81:141-149.
26. David S, Zaks JM. Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology. 1986;37:86-91.
27. Burger AJ, Horton DP, LeJemtel T, etal. Effect of nesiritide (b-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the precedent study. Am Heart J. 2002;144:1102-1108.
28. Aranda JM Jr, Schofield RS, Pauly DF, etal. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003;145:324-329.
29. Toma M, Starling RC. Inotropic therapy for end-stage heart failure patients. Curr Treat Options Cardiovasc Med. 2010;12:409-419.
30. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. Am Heart J. 1998;135:S293-S309.
31. Nohria A, Tsang SW, Fang JC, etal. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-1804.
32. Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation. 1977;56:468-472.
33. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003;108:492-497.
34. Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D. Care processes and clinical outcomes of continuous outpatient support with inotropes (cosi) in patients with refractory endstage heart failure. J Card Fail. 2003;9:180-187.
35. Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis RP, Leier CV. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J. 1983;106:29-34.
36. Cusick DA, Pfeifer PB, Quigg RJ. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am J Cardiol. 1998;82:1060-1065.
37. Capomolla S, Febo O, Opasich C, etal. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail. 2001;3:601-610.
38. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
39. Levinoff Roth SN, Moe G. Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure. Can J Cardiol. 1993;9:231-237.
40. Marius-Nunez AL, Heaney L, Fernandez RN, etal. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J. 1996;132:805-808.
41. Hatzizacharias A, Makris T, Krespi P, etal. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J. 1999;138:241-246.
42. Krell MJ, Kline EM, Bates ER, etal. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986;112:787-791.
43. Applefeld MM, Newman KA, Sutton FJ, etal. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J. 1987;114:589-595.
44. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J. 1998;135:121-129.
45. Roffman DS, Applefeld MM, Grove WR, etal. Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure. Clin Pharm. 1985;4:195-199.
46. Lopez-Candales AL, Carron C, Schwartz J. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. Clin Cardiol. 2004;27:23-28.
47. Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. 1998;63:682-685.
48. Erlemeier HH, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance. Cardiovasc Drugs Ther. 1992;6:391-398.
49. Oliva F, Latini R, Politi A, etal. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138:247-253.
50. Hauptman PJ, Mikolajczak P, George A, etal. Chronic inotropic therapy in end-stage heart failure. Am Heart J. 2006;152:1096. e1-e8.
51. Harjai KJ, Mehra MR, Ventura HO, etal. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes. Chest. 1997;112:1298-1303.
52. Brozena SC, Twomey C, Goldberg LR, etal. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. 2004;23:1082-1086.
53. Canver CC, Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thorac Surg. 2000;69:1823-1826.
54. Upadya S, Lee FA, Saldarriaga C, etal. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant. 2004;23:466-472.
55. Sindone AP, Keogh AM, Macdonald PS, McCosker CJ, Kaan AF. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J. 1997;134: 889-900.
56. Miller LW, Merkle EJ, Herrmann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med. 1990;18:S30-S33.
57. Elkayam U, Tasissa G, Binanay C, etal. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104.
58. Abraham WT, Adams KF, Fonarow GC, etal; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (adhere). J Am Coll Cardiol. 2005;46:57-64.
59. O'Connor CM, Gattis WA, Uretsky BF, etal. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (first). Am Heart J. 1999;138:78-86.
60. Rossinen J, Harjola VP, Siirila-Waris K, etal. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute Card Care. 2008;10:209-213.
61. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529.
62. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;(1):CD002230.
63. Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling RC. Prognosis on chronic dobutamine or milrinone infusions for stage d heart failure. Circ Heart Fail. 2009;2:320-324.
64. Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol. 1997;80:61-64.
65. Uretsky BF, Jessup M, Konstam MA, etal. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone multicenter trial group. Circulation. 1990;82:774-780.
66. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone investigators. Br Heart J. 1994;72:226-230.
67. Cohn JN, Goldstein SO, Greenberg BH, etal. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators. New Engl J Med. 1998;339:1810-1816.
68. Hampton JR, van Veldhuisen DJ, Kleber FX, etal. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
69. Packer M, Carver JR, Rodeheffer RJ, etal. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New Engl J Med. 1991;325:1468-1475.
70. Drakos SG, Kanakakis JV, Nanas S, etal. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol. 2009;53:157-161.
71. Nanas JN, Tsagalou EP, Kanakakis J, etal. Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest. 2004;125:1198-1204.
72. Tsagalou EP, Anastasiou-Nana MI, Terrovitis JV, etal. The long-term survival benefit conferred by intermittent dobutamine infusions and oral amiodarone is greater in patients with idiopathic dilated cardiomyopathy than with ischemic heart disease. Int J Cardiol. 2006;108:244-250.
73. Cuffe MS, Califf RM, Adams KF Jr, etal. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
74. Felker GM, Benza RL, Chandler AB, etal. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003.
75. Metra M, Eichhorn E, Abraham WT, etal. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30:3015-3026.
76. Feldman AM, Oren RM, Abraham WT, etal. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007;154:861-869.
77. Colucci WS, Sonnenblick EH, Adams KF, etal. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The milrinone multicenter trials investigators. J Am Coll Cardiol. 1993;22:113A-118A.
78. Massie B, Bourassa M, DiBianco R, etal. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 1985;71:963-971.
79. Narahara KA. Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Am Heart J. 1991;121:1471-1479.
80. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, etal. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;22:1564-1573.
81. Dubourg O, Delorme G, Hardy A, Beauchet A, Tarral A, Bourdarias JP. Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment. Int J Cardiol. 1990;28 Suppl 1: S33-S42; discussion S43.
82. Feldman AM, Bristow MR, Parmley WW, etal. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study group. New Engl J Med. 1993;329:149-155.
83. Likoff MJ, Weber KT, Andrews V, etal. Amrinone in the treatment of chronic cardiac failure. J Am Coll Cardiol. 1984;3:1282-1290.
84. Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J. 2001;141:266-273.
85. Xamoterol in severe heart failure. The xamoterol in severe heart failure study group. Lancet. 1990;336:1-6.
86. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol. 1984;4:855-866.
87. Khalife K, Zannad F, Brunotte F, etal. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation. Am J Cardiol. 1987;60:75C-79C.
88. Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol. In press 2014.